Bailard Inc. Sells 1,289 Shares of Sanofi (NASDAQ:SNY)

Bailard Inc. trimmed its holdings in shares of Sanofi (NASDAQ:SNYGet Rating) by 8.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,692 shares of the company’s stock after selling 1,289 shares during the quarter. Bailard Inc.’s holdings in Sanofi were worth $736,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Addison Advisors LLC lifted its position in shares of Sanofi by 5,277.8% during the fourth quarter. Addison Advisors LLC now owns 968 shares of the company’s stock worth $48,000 after purchasing an additional 950 shares during the last quarter. Northwest Investment Counselors LLC bought a new stake in shares of Sanofi during the fourth quarter worth $49,000. FSB Premier Wealth Management Inc. bought a new stake in shares of Sanofi during the fourth quarter worth $49,000. Fieldpoint Private Securities LLC raised its holdings in shares of Sanofi by 19.4% in the third quarter. Fieldpoint Private Securities LLC now owns 1,720 shares of the company’s stock valued at $83,000 after acquiring an additional 280 shares in the last quarter. Finally, AdvisorNet Financial Inc raised its holdings in shares of Sanofi by 13.7% in the fourth quarter. AdvisorNet Financial Inc now owns 2,152 shares of the company’s stock valued at $108,000 after acquiring an additional 260 shares in the last quarter. Institutional investors and hedge funds own 12.82% of the company’s stock.

Several analysts recently weighed in on SNY shares. Liberum Capital upgraded Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, January 25th. Credit Suisse Group lifted their price objective on Sanofi from €96.00 ($100.00) to €105.00 ($109.38) in a report on Monday, March 28th. Guggenheim lifted their price objective on Sanofi from €121.00 ($126.04) to €127.00 ($132.29) in a report on Monday, May 2nd. Morgan Stanley lifted their price objective on Sanofi from €110.00 ($114.58) to €112.00 ($116.67) in a report on Friday, April 22nd. Finally, Stifel Nicolaus started coverage on Sanofi in a report on Monday, February 28th. They issued a “buy” rating for the company. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Sanofi currently has a consensus rating of “Buy” and an average price target of $99.86.

Shares of SNY stock opened at $52.56 on Tuesday. Sanofi has a fifty-two week low of $46.92 and a fifty-two week high of $58.10. The firm has a market capitalization of $132.83 billion, a price-to-earnings ratio of 17.01, a PEG ratio of 1.06 and a beta of 0.50. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.03 and a current ratio of 1.44. The stock’s 50-day simple moving average is $53.00 and its 200-day simple moving average is $51.53.

The firm also recently declared an annual dividend, which will be paid on Wednesday, June 8th. Stockholders of record on Thursday, May 5th will be paid a dividend of $1.7968 per share. The ex-dividend date is Wednesday, May 4th. This represents a dividend yield of 2.7%. Sanofi’s payout ratio is 42.07%.

About Sanofi (Get Rating)

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.

See Also

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.